Biography

Professor Seng Gee Lim, FRACP, FRCP, FAMS, MD, is Director of Hepatology at the Division of Gastroenterology and Hepatology, National University Health System, Singapore, and was previously Chief of Division. He graduated in 1980 from Monash Medical School completed his research MD at the Royal Free Hospital.

He is a member of the editorial boards for, Journal of Viral Hepatitis, J of Viral Eradication. He is also on the Advisory Board of Gilead Sciences, Roche, AusperBio, GlaxoSmithkline, Aligos, Sysmex, Grifols and Abbott Diagnostics.

He is currently chairman of the Singapore Hepatology Conference and Science of HBV Cure Conference, and was previously the Chairman of the Asia Pacific Association for Study of the Liver (APASL) Liver Week 2013 Congress. He served as Governing Council member from 2014-2018 of the International Association for Study of Liver (IASL), and has been appointed to the AASLD Asia Pacific Regional Advisory Council in 2018. He is also governing council board member of International Coalition for Eradication for Hepatitis B (ICE-HBV) and a steering committee member of HBV Forum. He is a council member of the Global Hepatitis Summit [International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)]. He is Scientific Advisory Board member for ANRS Maladies Infectieuses Emergentes, France and member of liver disease committee of World Gastroenterology Organisation. He is faculty at the Asia Pacific EBM workshop. He was recently awarded the APDWF Okuda Lectureship in 2024.

His research includes clinical trials of new treatments for chronic hepatitis B and translational research in viral hepatitis, involving molecular biology and immunology of hepatitis B, and HBV elimination. He has published 310 peer reviewed publications and secured peer review grant funding worth SGD $58 Million (USD$45M), including the award of a SGD $25 million National Translational Clinical Research grant in 2015 to investigate eradication of HBV, which and LCG $10M in 2020. In 2018 he was awarded the NMRC CSA twice and the STaR award in 2025 for research in HBV. His H index is 71